Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


GREY:BIOAF - Post by User

Comment by buddy2021on Mar 23, 2021 12:49pm
181 Views
Post# 32858634

RE:Presented with end of CY Q1 days away. +- a few days

RE:Presented with end of CY Q1 days away. +- a few days
Pasted table disappeared? See the below. (I know this was previously posted but worth repeating.)

Upcoming R&D Milestones
Program                                         Milestone                                         Anticipated Timing
xB3-004 IL-1RA                      EAE (Multiple Sclerosis)model read-out         Q1, CY2021
xB3-007 glucocerebrosidase ERT  BBB data                                                 Q1, CY2021
                                                        Disease model read-out                          Q3, CY2021
xB3-Progranulin                               BBB data                                                Q1, CY2021
                                                         FTD disease model read-out                  Q3, CY2021

Value accretive milestones, supportive of additional
partnerships and further technology validation
<< Previous
Bullboard Posts
Next >>